Hi Colin

Yes I know, I worked with David Moss at Birkbeck for many years to
develop software to process the DS data.  I think the point of using
finely collimated SRS X-rays (from the Daresbury SRS of course!) was to
scale down the spot size of both the Bragg & acoustic peaks by the same
factor, so that the peak integration included both contributions in the
'peak' region of the integration box in Mosflm, in order to prevent the
tail of the acoustic peak from straying into the 'background' region of
the adjacent spots.

David had developed an empirical theory to model the air, solvent,
Compton & acoustic contributions and correct the integrated data for
these, without background correction of course since the optic DS
background was ultimately to be our data!  It was only the Bragg & optic
DS components that were interesting from a structure/function point of
view.  I don't recall any discussion that we could get a handle on
separating the Bragg and acoustic components by changing the divergence
of the beam or the distance.

Cheers

-- Ian

> -----Original Message-----
> From: [log in to unmask] 
> [mailto:[log in to unmask]] On Behalf Of 
> [log in to unmask]
> Sent: 26 November 2009 11:54
> To: Ian Tickle; [log in to unmask]
> Subject: RE: [ccp4bb] decrease of background with distance?
> 
> 
>  Ian
> Maybe - maybe not. 
> Investigations of acoustic and optical components of diffuse scatter
> from proteins were carried out in the 80s and 90s including of course
> work at Birkbeck (which I am sure you are aware of)
> 
> Refs can be found in Glover et. al. Acta Cryst. (1991). B47, 960-968.
> This paper includes the statement 
> "We have exploited the characteristic fine collimation of synchrotron
> radiation in the collection of data in which the acoustic scattering
> contributions are minimized
> to assess the effect on model refinement"
> 
> I think if the acoustic mode is due to correlations extending over 6
> cells (say) then the width of the acoustic scatter will reflect this.
> The diffuse feature will spread out as the spots separate when the
> detector is moved back. However, as you say, separating them from the
> diffraction peak could still be a problem. Should this intensity be
> regarded as part of the Bragg peak or should it be subtracted from it?
> With a poorly collimated beam or close detector distance this problem
> does not arise as the acoustic scatter is in any case buried 
> in the rest
> of the Bragg peak.
> 
> Oh no - something else to argue about!
> 
>  Colin
> 
> 
> 
> -----Original Message-----
> From: CCP4 bulletin board [mailto:[log in to unmask]] On Behalf Of
> Ian Tickle
> Sent: 26 November 2009 11:20
> To: [log in to unmask]
> Subject: Re: [ccp4bb] decrease of background with distance?
> 
> > The source for the X-ray background are points along the air path 
> > post-collimator including the sample with loop and 
> cryoprotecdant (or 
> > capillary and mother liquor).  So the 1/r^2 falloff is 
> noticable going
> 
> > from 100 mm to 200 mm.  The same counts in a 2x2 pixel area is now 
> > seen in a 4x4 pixel area.
> 
> Hi Jim,
> 
> I think it may be a bit more complicated than this because the
> background contribution from the crystalline scattering consists of
> non-Bragg elastic ('diffuse') scattering, plus inelastic ('Compton')
> scattering, though the latter is probably small & can be ignored.  DS
> consists of a number of contributions, notably the 'optic' 
> component due
> to short range correlated displacements (e.g. of secondary structure
> elements), and the 'acoustic' component due to longer range correlated
> displacements of whole molecules in adjacent unit cells (i.e. 
> scattering
> by lattice phonons).  Now the 'optic' component can be regarded as
> attached to the reciprocal lattice, so does scale exactly in 
> the way you
> describe.  However the acoustic component probably represents the
> biggest contributor to the X-ray background under normal 
> conditions and
> is responsible for the 'tails' under the Bragg spots; in fact the
> acoustic DS peaks right under the Bragg spots & there's no 
> practical way
> of separating them, because AFAIK (though I could be wrong) 
> the acoustic
> peaks scale with the Bragg spots.  I don't think it's possible (though
> admittedly I've never tried) to separate the acoustic DS 
> tails from the
> spots merely by moving the detector further away as you seem to be
> implying!  I'm by no means an expert on dynamical scattering 
> theory so I
> could be talking nonsense!
> 
> > The source for Bragg reflections at a synchtrotron is upstream a 
> > couple dozen meters.  The divergence is not large as well, so the 
> > spread in the spots (for a source ~30 meters upstream) goes from 
> > 1/(30.1 *
> > 30.1)^2 to
> > 1/(30.2 * 30.2)^2 which is really not that noticable.
> 
> I'm genuinely confused by this because I thought the whole point of
> modern focusing optics (or at least the confocal mirror design) is to
> focus the beam onto (or close to) the sample, in which case 
> wouldn't the
> photons diverge from the 'virtual source' (actually a real 
> image of the
> real source) at the crystal, instead of from the real source?  So then
> Bragg spots (and therefore also the acoustic DS) should 
> diverge from the
> position of this virtual source?
> 
> Cheers
> 
> -- Ian
> 
> 
> Disclaimer
> This communication is confidential and may contain privileged
> information intended solely for the named addressee(s). It may not be
> used or disclosed except for the purpose for which it has 
> been sent. If
> you are not the intended recipient you must not review, use, disclose,
> copy, distribute or take any action in reliance upon it. If you have
> received this communication in error, please notify Astex Therapeutics
> Ltd by emailing [log in to unmask] and destroy all copies
> of the message and any attached documents. 
> Astex Therapeutics Ltd monitors, controls and protects all 
> its messaging
> traffic in compliance with its corporate email policy. The Company
> accepts no liability or responsibility for any onward transmission or
> use of emails and attachments having left the Astex 
> Therapeutics domain.
> Unless expressly stated, opinions in this message are those of the
> individual sender and not of Astex Therapeutics Ltd. The recipient
> should check this email and any attachments for the presence 
> of computer
> viruses. Astex Therapeutics Ltd accepts no liability for damage caused
> by any virus transmitted by this email. E-mail is susceptible to data
> corruption, interception, unauthorized amendment, and tampering, Astex
> Therapeutics Ltd only send and receive e-mails on the basis that the
> Company is not liable for any such alteration or any consequences
> thereof.
> Astex Therapeutics Ltd., Registered in England at 436 
> Cambridge Science
> Park, Cambridge CB4 0QA under number 3751674
> 
> --
> This e-mail and any attachments may contain confidential, 
> copyright and or privileged material, and are for the use of 
> the intended addressee only. If you are not the intended 
> addressee or an authorised recipient of the addressee please 
> notify us of receipt by returning the e-mail and do not use, 
> copy, retain, distribute or disclose the information in or 
> attached to the e-mail.
> Any opinions expressed within this e-mail are those of the 
> individual and not necessarily of Diamond Light Source Ltd.
> Diamond Light Source Ltd. cannot guarantee that this e-mail 
> or any attachments are free from viruses and we cannot accept 
> liability for any damage which you may sustain as a result of 
> software viruses which may be transmitted in or with the message.
> Diamond Light Source Limited (company no. 4375679). 
> Registered in England and Wales with its registered office at 
> Diamond House, Harwell Science and Innovation Campus, Didcot, 
> Oxfordshire, OX11 0DE, United Kingdom
> 
> 
> 


Disclaimer
This communication is confidential and may contain privileged information intended solely for the named addressee(s). It may not be used or disclosed except for the purpose for which it has been sent. If you are not the intended recipient you must not review, use, disclose, copy, distribute or take any action in reliance upon it. If you have received this communication in error, please notify Astex Therapeutics Ltd by emailing [log in to unmask] and destroy all copies of the message and any attached documents. 
Astex Therapeutics Ltd monitors, controls and protects all its messaging traffic in compliance with its corporate email policy. The Company accepts no liability or responsibility for any onward transmission or use of emails and attachments having left the Astex Therapeutics domain.  Unless expressly stated, opinions in this message are those of the individual sender and not of Astex Therapeutics Ltd. The recipient should check this email and any attachments for the presence of computer viruses. Astex Therapeutics Ltd accepts no liability for damage caused by any virus transmitted by this email. E-mail is susceptible to data corruption, interception, unauthorized amendment, and tampering, Astex Therapeutics Ltd only send and receive e-mails on the basis that the Company is not liable for any such alteration or any consequences thereof.
Astex Therapeutics Ltd., Registered in England at 436 Cambridge Science Park, Cambridge CB4 0QA under number 3751674